CTOs on the Move

Bristol-Myers Squibb

www.bms.com

 
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious and life-threatening diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others. Through the Bristol-Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world`s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.bms.com
  • 345 Park Avenue
    New York, NY USA 10154
  • Phone: 212.546.4000

Executives

Name Title Contact Details
Staci Hargraves
SVP, Head of Transformation, Drug Development Profile
Ami Mehta
Associate Director, IT Lead for Cell Therapy Medical Affairs/Ex US Commercial Profile
Rosimar Lehr
Associate Director, Contract Lead, IT Services, Agile Sourcing Profile
Michael Morris
Executive Director, Global Procurement IT Profile
Ari Hamalian
Executive Director IT Risk Operations and Supplier Resilience Profile

Jobs

Head of Global Talent Acquisition

Bristol-Myers Squibb Princeton, NJ
Job Description

The Head Global Talent Acquisition will report to the Head of Global Talent and Organizational Effectiveness who reports to the company’s Chief Human Resources Officer. The incumbent will lead a global team of 30+ BMS individuals and 110+ recruitment professionals working for Cielo (US) and Alexander Mann ...

Funding

Bristol-Myers Squibb raised $20.2M on 12/17/2020

Similar Companies

Octant Bio

Octant is a well-backed team of experienced scientists and entrepreneurs exploring new frontiers of biology. We are applying next-generation DNA sequencing, gene synthesis, and gene editing to revolutionize drug discovery in a quest for safer, more effective, and cheaper drugs.

XtalPi

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.

Vascular Biogenics Limited Therapeutics

VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.

Tolerx

Tolerx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.